Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva

NCT ID NCT07741435

Diagnosis Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare results from about 3,250 adults—some with biopsy-confirmed solid tumors and some cancer-free—to measure the test's accuracy. If it works, this could become a low-cost tool for catching multiple cancer types early and monitoring for relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methylscape DNA methylation assay (a rapid diagnostic test measuring DNA methylation patterns in body fluids)
What this could lead to
If successful, this could lead to a simple, affordable blood, urine, or saliva test that detects multiple cancer types early and identifies where the cancer started, potentially improving survival odds.
What could go wrong
This is an observational study, not a treatment trial, so it won't cure cancer directly. The test may not be accurate enough in real-world settings, and results from this Colombian population may not apply globally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Colombian adults (≥18 years) with biopsy-confirmed solid tumors selected by local incidence (emphasis on breast, lung, and gastric cancer) and age- and sex-matched cancer-free volunteers, recruited at a single cancer center (CTIC) in Bogotá, Colombia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Willing and able to participate and to provide the required samples (blood, urine, saliva) and demographic information (age, sex, race/ethnicity, BMI). * Able to provide written informed consent for participation and for use of biological samples. For CTIC Biobank samples, prior research-use consent is verified. * Demographic/anthropometric comparability (race, ethnicity, BMI) with other participants; race/ethnicity by self-identification (WHO and national census categories); BMI per WHO categories. Inclusion - Cancer cohort: * Cancer diagnosis confirmed within 90 days prior to sample collection. * Biopsy-proven malignancy with radiological staging. * No anticancer treatment at the time of collection or within the previous 3 years. * Inclusion - Cancer-free (healthy) cohort: * No cancer diagnosis or treatment in the previous 3 years (ICD-O-3 behavior code 2 or 3). * Not under evaluation for suspected cancer (verified by medical record review or additional medical evaluation). * Subjects with benign tumors (code 0) or tumors of uncertain behavior (code 1) may be included if there is no clinical evidence of progression or malignancy. Additional criteria - tumor-burden monitoring (Sub-study 2b): * Biopsy-confirmed cancer. * ECOG performance status ≤ 2. Exclusion Criteria (both cohorts): * Failure to meet the general or cohort-specific inclusion criteria. * Pregnancy. * Organ transplant recipients. * Use of demethylating agents (azacitidine, decitabine) or cytotoxic agents (including for autoimmune/inflammatory conditions). * Prior or ongoing anticancer therapy: cancer surgery beyond that needed for diagnosis; local, regional, or systemic chemotherapy (including chemoembolization); targeted therapy; immunotherapy (including cancer vaccines); hormonal therapy; or radiotherapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm breast neoplasm cervical cancer colorectal neoplasm gastric neoplasm head and neck neoplasm Head and Neck Neoplasms lung neoplasm neoplasm Neoplasm Recurrence, Local Neoplasm, Residual urinary system neoplasm Uterine Cervical Neoplasms uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Colorectal neoplasms Early detection of cancer Head and neck neoplasms Lung neoplasms Neoplasm recurrence, local Neoplasms Solid tumor Stomach neoplasms Urologic neoplasms Uterine cervical neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fundación CTIC Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo

    RECRUITING

    Bogotá, Bogota D.C., 110131, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.